Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MaxSimil
- Development stage
- Phase 1
- Lead developer
- Neptune Wellness Solutions
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MaxSimil is a patented, monoglyceride-rich fish oil (MRFO) technology designed to enhance the absorption of omega-3 fatty acids. Developed by Ingredia, the technology employs a proprietary enzymatic process that mimics human digestion by converting standard fish oil triglycerides into monoglycerides. This "pre-digested" form allows for direct absorption into the intestinal tract without the prerequisite of emulsification by bile salts or breakdown by pancreatic lipase. Consequently, MaxSimil demonstrates significantly higher bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) compared to traditional ethyl ester or triglyceride forms, making it particularly beneficial for individuals with digestive sensitivities or malabsorption syndromes. It is marketed as a premium nutraceutical ingredient for cardiovascular support, cognitive health, and inflammatory modulation.
- Brand names
- MaxSimilOmegaMonoPure
- Other names
- Monoglyceride-rich fish oilMRFO
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on MaxSimil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MaxSimil.